Empagliflozin

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Empagliflozin

Examples of brand names: Jardiance [EU/DE]

ATC code: A10BK03

Main use (for orientation): Diabetes; heart/renal failure

Documented research summary

Within the documented search scope, no sufficiently attributable cannabinoid pair is established for Empagliflozin. The structured assessment distinguishes documented drug context from the absence of specific interaction evidence. Missing data do not establish safety.

Uncertainties and limitations

Do not present general CBD-mediated UGT inhibition as a measured empagliflozin interaction. Do not independently change prescribed medicines on the basis of this research dataset.

Structured assessment

Category: Drug context

Cannabinoid scope: No specifically substantiated pair involving a registered cannabinoid in the material assessed; no claim that all 28 cannabinoids were comprehensively reviewed simultaneously.

Evidence status: Drug properties supported by product information; insufficient evidence for a specific cannabinoid–drug pair effect.

Mechanism / drug context: Glucuronidation via UGT2B7, UGT1A3, UGT1A8 and UGT1A9; transporters including P-glycoprotein/BCRP.

Type of supporting material: Product information and documented individual literature screening; no clinical pair trial approved for use as evidence.

Clinical interpretation: A specific cannabinoid influence on empagliflozin is not established.

Context: The evaluated experimental combination concerns the synthetic CB1 compound monlunabant and is not evidence for empagliflozin with CBD or THC.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [VD_LABEL_D0253]: Original product information: drug context, not evidence for a cannabinoid–drug pair

Statement supported: Glucuronidation via UGT2B7, UGT1A3, UGT1A8 and UGT1A9; transporters including P-glycoprotein/BCRP.

Source: JARDIANCE (EMPAGLIFLOZIN) TABLET, FILM COATED [REDPHARM DRUG] – DailyMed SPL [VD_LABEL_D0253]

Source role [VD_MED_40650347]: Documented research / scope-distinction context; no cannabinoid–drug pair evidence approved for use

Statement supported: The evaluated experimental combination concerns the synthetic CB1 compound monlunabant and is not evidence for empagliflozin with CBD or THC.

Source: Blockade of cannabinoid CB1 receptors potentiates the anti-fibrotic effects mediated by SGLT2 inhibition in a mouse model of diabetic nephropathy. [VD_MED_40650347]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: All individual review fields read. Original product information was rechecked only in the relevant pharmacokinetic/interaction excerpts; no complete recertification of all labels or worldwide full-text search. Literature access was based on the previously documented review; only the listed web sources were additionally read in this round. Do not present general CBD-mediated UGT inhibition as a measured empagliflozin interaction.

Separately recorded findings

No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.

References and access status

[VD_LABEL_D0253] JARDIANCE (EMPAGLIFLOZIN) TABLET, FILM COATED [REDPHARM DRUG] – DailyMed SPL

Original source / bibliographic reference

Authors: Marketing authorisation holder / label provider according to the linked DailyMed product information

Year: 2026

Source type: Regulatory product information (US SPL)

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[VD_MED_40650347] Blockade of cannabinoid CB1 receptors potentiates the anti-fibrotic effects mediated by SGLT2 inhibition in a mouse model of diabetic nephropathy.

Original source / bibliographic reference

Authors: Pointeau O, Ba AI, Geissler A, Barbosa R, Basu A, Muhammad A, Nivot M, Loriot M, Leemput J, Passilly-Degrace P, Causse S, Demizieux L, François H, Vergès B, Duan J, Gaucher G, Harvey M, Degrace P, Crater G, Cinar R, Jourdan T.

Year: 2025

Source type: Journal Article

DOI: 10.1111/bph.70118

PMID: 40650347

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility